Malaria is one of the most important diseases in the world, causing hundreds of millions of cases, and approximately 1 million deaths annually. SIGHTM’s broad malaria agenda supports malaria elimination & control through strategic planning, and operational support for national and international initiatives. SIGHTM is affiliated with Sanaria Inc. and supports their goal to develop increased capacity worldwide, particularly in Africa, for conducting controlled human malaria infections (CHMIs) for assessment of new malaria drugs, vaccines, and diagnostics, and to assess the impact of innate and acquired human responses on malaria infections. An immediate need is optimization of administration by needle and syringe of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ), a product called PfSPZ Challenge. Teams from clinical centers in Africa, Europe and North America are now working to achieve this goal.